Pegaspargase biosimilar - Xbrane

Drug Profile

Pegaspargase biosimilar - Xbrane

Latest Information Update: 30 Oct 2015

Price : $50

At a glance

  • Originator Xbrane
  • Class Amidohydrolases; Antineoplastics; Polyethylene glycols
  • Mechanism of Action Aspartate-ammonia ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Acute myeloid leukaemia

Most Recent Events

  • 30 Oct 2015 Preclinical trials in Acute myeloid leukaemia in Sweden (Parenteral)
  • 30 Oct 2015 Preclinical trials in Acute lymphoblastic leukaemia in Sweden (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top